FDA Generic Rx Reforms Contribute To Medicare Budget Squeeze

CBO is predicting only minor savings to the Medicare prescription drug program through Waxman/Hatch reforms contained in the Senate and House versions of the Medicare bill in light of previous reforms announced by FDA